|
1
|
Brenner H, Rothenbacher D and Arndt V:
Epidemiology of stomach cancer. Methods Mol Biol. 472:467–477.
2009. View Article : Google Scholar
|
|
2
|
Leung WK, Wu MS, Kakugawa Y, Kim JJ, Yeoh
KG, Goh KL, Wu KC, Wu DC, Sollano J, Kachintorn U, et al Asia
Pacific Working Group on Gastric Cancer: Screening for gastric
cancer in Asia: Current evidence and practice. Lancet Oncol.
9:279–287. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nakamura J, Tanaka T, Kitajima Y, Noshiro
H and Miyazaki K: Methylation-mediated gene silencing as biomarkers
of gastric cancer: A review. World J Gastroenterol. 20:11991–12006.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sharma S, Kelly TK and Jones PA:
Epigenetics in cancer. Carcinogenesis. 31:27–36. 2010. View Article : Google Scholar :
|
|
5
|
Suzuki MM and Bird A: DNA methylation
landscapes: Provocative insights from epigenomics. Nat Rev Genet.
9:465–476. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Eden A, Gaudet F, Waghmare A and Jaenisch
R: Chromosomal instability and tumors promoted by DNA
hypomethylation. Science. 300:4552003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Karpf AR and Matsui S: Genetic disruption
of cytosine DNA methyltransferase enzymes induces chromosomal
instability in human cancer cells. Cancer Res. 65:8635–8639. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Schulz WA: L1 retrotransposons in human
cancers. J Biomed Biotechnol. 2006:836722006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Esteller M: Epigenetics in cancer. N Engl
J Med. 358:1148–1159. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ehrlich M: DNA methylation in cancer: Too
much, but also too little. Oncogene. 21:5400–5413. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Omenn GS: Strategies for plasma proteomic
profiling of cancers. Proteomics. 6:5662–5673. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Momparler RL and Bovenzi V: DNA
methylation and cancer. J Cell Physiol. 183:145–154. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Robertson DS: Cellular configuration of
DNA and cell division. Med Hypotheses. 57:344–353. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fuks F, Hurd PJ, Deplus R and Kouzarides
T: The DNA methyltransferases associate with HP1 and the SUV39H1
histone methyltransferase. Nucleic Acids Res. 31:2305–2312. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kouzarides T: Chromatin modifications and
their function. Cell. 128:693–705. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tan M, Luo H, Lee S, Jin F, Yang JS,
Montellier E, Buchou T, Cheng Z, Rousseaux S, Rajagopal N, et al:
Identification of 67 histone marks and histone lysine crotonylation
as a new type of histone modification. Cell. 146:1016–1028. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kouzarides T: SnapShot: Histone-modifying
enzymes. Cell. 131:822–822.e1. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gigek CO, Chen ES, Calcagno DQ, Wisnieski
F, Burbano RR and Smith MA: Epigenetic mechanisms in gastric
cancer. Epigenomics. 4:279–294. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ushijima T and Sasako M: Focus on gastric
cancer. Cancer Cell. 5:121–125. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Park JH, Park J, Choi JK, Lyu J, Bae MG,
Lee YG, Bae JB, Park DY, Yang HK, Kim TY, et al: Identification of
DNA methylation changes associated with human gastric cancer. BMC
Med Genomics. 4:822011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yoshida T, Yamashita S, Takamura-Enya T,
Niwa T, Ando T, Enomoto S, Maekita T, Nakazawa K, Tatematsu M,
Ichinose M, et al: Alu and Satα hypomethylation in Helicobacter
pylori-infected gastric mucosae. Int J Cancer. 128:33–39. 2011.
View Article : Google Scholar
|
|
22
|
Jang BG and Kim WH: Molecular pathology of
gastric carcinoma. Pathobiology. 78:302–310. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Leodolter A, Alonso S, González B, Ebert
MP, Vieth M, Röcken C, Wex T, Peitz U, Malfertheiner P and Perucho
M: Somatic DNA Hypomethylation in H. pylori-associated high-risk
gastritis and gastric cancer: Enhanced somatic hypomethylation
associates with advanced stage cancer. Clin Transl Gastroenterol.
6:e852015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kosumi K, Baba Y, Ishimoto T, Harada K,
Miyake K, Izumi D, Tokunaga R, Murata A, Eto K, Sugihara H, et al:
Relationship between LINE-1 hypomethylation and Helicobacter pylori
infection in gastric mucosae. Med Oncol. 32:1172015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shigaki H, Baba Y, Watanabe M, Murata A,
Iwagami S, Miyake K, Ishimoto T, Iwatsuki M and Baba H: LINE-1
hypomethylation in gastric cancer, detected by bisulfite
pyrosequencing, is associated with poor prognosis. Gastric Cancer.
16:480–487. 2013. View Article : Google Scholar :
|
|
26
|
Xiang S, Liu Z, Zhang B, Zhou J, Zhu BD,
Ji J and Deng D: Methylation status of individual CpG sites within
Alu elements in the human genome and Alu hypomethylation in gastric
carcinomas. BMC Cancer. 10:442010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yuasa Y, Nagasaki H, Oze I, Akiyama Y,
Yoshida S, Shitara K, Ito S, Hosono S, Watanabe M, Ito H, et al:
Insulin-like growth factor 2 hypomethylation of blood leukocyte DNA
is associated with gastric cancer risk. Int J Cancer.
131:2596–2603. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hansen KD, Timp W, Bravo HC, Sabunciyan S,
Langmead B, McDonald OG, Wen B, Wu H, Liu Y, Diep D, et al:
Increased methylation variation in epigenetic domains across cancer
types. Nat Genet. 43:768–775. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Song SH, Jong HS, Choi HH, Kang SH, Ryu
MH, Kim NK, Kim WH and Bang YJ: Methylation of specific CpG sites
in the promoter region could significantly down-regulate
p16INK4a expression in gastric adenocarcinoma. Int J
Cancer. 87:236–240. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shu XS, Geng H, Li L, Ying J, Ma C, Wang
Y, Poon FF, Wang X, Ying Y, Yeo W, et al: The epigenetic modifier
PRDM5 functions as a tumor suppressor through modulating
WNT/β-catenin signaling and is frequently silenced in multiple
tumors. PLoS One. 6:e273462011. View Article : Google Scholar
|
|
31
|
Joo JK, Kim SH, Kim HG, Kim DY, Ryu SY,
Lee KH and Lee JH: CpG methylation of transcription factor 4 in
gastric carcinoma. Ann Surg Oncol. 17:3344–3353. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jung HY, Jung KC, Shim YH, Ro JY and Kang
GH: Methylation of the hMLH1 promoter in multiple gastric
carcinomas with microsatellite instability. Pathol Int. 51:445–451.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yousuf A, Bhat MY, Pandith AA, Afroze D,
Khan NP, Alam K, Shah P, Shah MA and Mudassar S: MGMT gene
silencing by promoter hypermethylation in gastric cancer in a high
incidence area. Cell Oncol (Dordr). 37:245–252. 2014. View Article : Google Scholar
|
|
34
|
Cheng YY, Yu J, Wong YP, Man EP, To KF,
Jin VX, Li J, Tao Q, Sung JJ, Chan FK, et al: Frequent epigenetic
inactivation of secreted frizzled-related protein 2 (SFRP2) by
promoter methylation in human gastric cancer. Br J Cancer.
97:895–901. 2007.PubMed/NCBI
|
|
35
|
Nojima M, Suzuki H, Toyota M, Watanabe Y,
Maruyama R, Sasaki S, Sasaki Y, Mita H, Nishikawa N, Yamaguchi K,
et al: Frequent epigenetic inactivation of SFRP genes and
constitutive activation of Wnt signaling in gastric cancer.
Oncogene. 26:4699–4713. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ebert MP, Yu J, Hoffmann J, Rocco A,
Röcken C, Kahmann S, Müller O, Korc M, Sung JJ and Malfertheiner P:
Loss of beta-catenin expression in metastatic gastric cancer. J
Clin Oncol. 21:1708–1714. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Oshimo Y, Kuraoka K, Nakayama H, Kitadai
Y, Yoshida K, Chayama K and Yasui W: Epigenetic inactivation of
SOCS-1 by CpG island hypermethylation in human gastric carcinoma.
Int J Cancer. 112:1003–1009. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kim TY, Lee HJ, Hwang KS, Lee M, Kim JW,
Bang YJ and Kang GH: Methylation of RUNX3 in various types of human
cancers and premalignant stages of gastric carcinoma. Lab Invest.
84:479–484. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Byun DS, Lee MG, Chae KS, Ryu BG and Chi
SG: Frequent epigenetic inactivation of RASSF1A by aberrant
promoter hypermethylation in human gastric adenocarcinoma. Cancer
Res. 61:7034–7038. 2001.PubMed/NCBI
|
|
40
|
Hayashi K, Yokozaki H, Goodison S, Oue N,
Suzuki T, Lotan R, Yasui W and Tahara E: Inactivation of retinoic
acid receptor beta by promoter CpG hypermethylation in gastric
cancer. Differentiation. 68:13–21. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yu J, Tao Q, Cheng YY, Lee KY, Ng SS,
Cheung KF, Tian L, Rha SY, Neumann U, Röcken C, et al: Promoter
methylation of the Wnt/beta-catenin signaling antagonist Dkk-3 is
associated with poor survival in gastric cancer. Cancer. 115:49–60.
2009. View Article : Google Scholar
|
|
42
|
Nishigaki M, Aoyagi K, Danjoh I, Fukaya M,
Yanagihara K, Sakamoto H, Yoshida T and Sasaki H: Discovery of
aberrant expression of R-RAS by cancer-linked DNA hypomethylation
in gastric cancer using microarrays. Cancer Res. 65:2115–2124.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Mulero-Navarro S and Esteller M:
Epigenetic biomarkers for human cancer: The time is now. Crit Rev
Oncol Hematol. 68:1–11. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Oue N, Matsumura S, Nakayama H, Kitadai Y,
Taniyama K, Matsusaki K and Yasui W: Reduced expression of the TSP1
gene and its association with promoter hypermethylation in gastric
carcinoma. Oncology. 64:423–429. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ganesan K, Ivanova T, Wu Y, Rajasegaran V,
Wu J, Lee MH, Yu K, Rha SY, Chung HC, Ylstra B, et al: Inhibition
of gastric cancer invasion and metastasis by PLA2G2A, a novel
beta-catenin/TCF target gene. Cancer Res. 68:4277–4286. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Chan AW, Chan MW, Lee TL, Ng EK, Leung WK,
Lau JY, Tong JH, Chan FK and To KF: Promoter hypermethylation of
Death-associated protein-kinase gene associated with advance stage
gastric cancer. Oncol Rep. 13:937–941. 2005.PubMed/NCBI
|
|
47
|
Yu J, Cheng YY, Tao Q, Cheung KF, Lam CN,
Geng H, Tian LW, Wong YP, Tong JH, Ying JM, et al: Methylation of
protocadherin 10, a novel tumor suppressor, is associated with poor
prognosis in patients with gastric cancer. Gastroenterology.
136:640–51.e1. 2009. View Article : Google Scholar
|
|
48
|
Hu X, Sui X, Li L, Huang X, Rong R, Su X,
Shi Q, Mo L, Shu X, Kuang Y, et al: Protocadherin 17 acts as a
tumour suppressor inducing tumour cell apoptosis and autophagy, and
is frequently methylated in gastric and colorectal cancers. J
Pathol. 229:62–73. 2013. View Article : Google Scholar
|
|
49
|
Haruki S, Imoto I, Kozaki K, Matsui T,
Kawachi H, Komatsu S, Muramatsu T, Shimada Y, Kawano T and Inazawa
J: Frequent silencing of protocadherin 17, a candidate tumour
suppressor for esophageal squamous cell carcinoma. Carcinogenesis.
31:1027–1036. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Hiraki M, Kitajima Y, Koga Y, Tanaka T,
Nakamura J, Hashiguchi K, Noshiro H and Miyazaki K: Aberrant gene
methylation is a biomarker for the detection of cancer cells in
peritoneal wash samples from advanced gastric cancer patients. Ann
Surg Oncol. 18:3013–3019. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Xu L, Li X, Chu ES, Zhao G, Go MY, Tao Q,
Jin H, Zeng Z, Sung JJ and Yu J: Epigenetic inactivation of BCL6B,
a novel functional tumour suppressor for gastric cancer, is
associated with poor survival. Gut. 61:977–985. 2012. View Article : Google Scholar
|
|
52
|
Xie B, Zhou J, Shu G, Liu DC, Zhou J, Chen
J and Yuan L: Restoration of klotho gene expression induces
apoptosis and autophagy in gastric cancer cells: Tumor suppressive
role of klotho in gastric cancer. Cancer Cell Int. 13:182013.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Kwon OH, Park JL, Baek SJ, Noh SM, Song
KS, Kim SY and Kim YS: Aberrant upregulation of ASCL2 by promoter
demethylation promotes the growth and resistance to 5-fluorouracil
of gastric cancer cells. Cancer Sci. 104:391–397. 2013. View Article : Google Scholar
|
|
54
|
Gigek CO, Lisboa LC, Leal MF, Silva PN,
Lima EM, Khayat AS, Assumpção PP, Burbano RR and Smith MA: SMARCA5
methylation and expression in gastric cancer. Cancer Invest.
29:162–166. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Xiong HL, Liu XQ, Sun AH, He Y, Li J and
Xia Y: Aberrant DNA methylation of P16, MGMT, hMLH1 and hMSH2 genes
in combination with the MTHFR C677T genetic polymorphism in gastric
cancer. Asian Pac J Cancer Prev. 14:3139–3142. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Hamai Y, Oue N, Mitani Y, Nakayama H, Ito
R, Matsusaki K, Yoshida K, Toge T and Yasui W: DNA hypermethylation
and histone hypoacetylation of the HLTF gene are associated with
reduced expression in gastric carcinoma. Cancer Sci. 94:692–698.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Wang L, Xie L, Wang J, Shen J and Liu B:
Correlation between the methylation of SULF2 and WRN promoter and
the irinotecan chemosensitivity in gastric cancer. BMC
Gastroenterol. 13:1732013. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Ivanova T, Zouridis H, Wu Y, Cheng LL, Tan
IB, Gopalakrishnan V, Ooi CH, Lee J, Qin L, Wu J, et al: Integrated
epigenomics identifies BMP4 as a modulator of cisplatin sensitivity
in gastric cancer. Gut. 62:22–33. 2013. View Article : Google Scholar
|
|
59
|
Zouridis H, Deng N, Ivanova T, Zhu Y, Wong
B, Huang D, Wu YH, Wu Y, Tan IB, Liem N, et al: Methylation
subtypes and large-scale epigenetic alterations in gastric cancer.
Sci Transl Med. 4:156ra1402012. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Selaru FM, David S, Meltzer SJ and
Hamilton JP: Epigenetic events in gastrointestinal cancer. Am J
Gastroenterol. 104:1910–1912. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Yamamoto E, Suzuki H, Takamaru H, Yamamoto
H, Toyota M and Shinomura Y: Role of DNA methylation in the
development of diffuse-type gastric cancer. Digestion. 83:241–249.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Cavallaro U and Christofori G:
Multitasking in tumor progression: Signaling functions of cell
adhesion molecules. Ann NY Acad Sci. 1014:58–66. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Zong L and Seto Y: CpG island methylator
phenotype, Helicobacter pylori, Epstein-Barr virus, and
microsatellite instability and prognosis in gastric cancer: A
systematic review and meta-analysis. PLoS One. 9:e860972014.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Ding WJ, Fang JY, Chen XY and Peng YS: The
expression and clinical significance of DNA methyltransferase
proteins in human gastric cancer. Dig Dis Sci. 53:2083–2089. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Yang J, Wei X, Wu Q, Xu Z, Gu D, Jin Y,
Shen Y, Huang H, Fan H and Chen J: Clinical significance of the
expression of DNA methyltransferase proteins in gastric cancer. Mol
Med Rep. 4:1139–1143. 2011.PubMed/NCBI
|
|
66
|
Cao XY, Ma HX, Shang YH, Jin MS, Kong F,
Jia ZF, Cao DH, Wang YP, Suo J and Jiang J: DNA methyltransferase3a
expression is an independent poor prognostic indicator in gastric
cancer. World J Gastroenterol. 20:8201–8208. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Cui H, Zhao C, Gong P, Wang L, Wu H, Zhang
K, Zhou R, Wang L, Zhang T, Zhong S, et al: DNA methyltransferase
3A promotes cell proliferation by silencing CDK inhibitor
p18INK4C in gastric carcinogenesis. Sci Rep.
5:137812015. View Article : Google Scholar
|
|
68
|
Ley TJ, Ding L, Walter MJ, McLellan MD,
Lamprecht T, Larson DE, Kandoth C, Payton JE, Baty J, Welch J, et
al: DNMT3A mutations in acute myeloid leukemia. N Engl J Med.
363:2424–2433. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Zang ZJ, Cutcutache I, Poon SL, Zhang SL,
McPherson JR, Tao J, Rajasegaran V, Heng HL, Deng N, Gan A, et al:
Exome sequencing of gastric adenocarcinoma identifies recurrent
somatic mutations in cell adhesion and chromatin remodeling genes.
Nat Genet. 44:570–574. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Kim MS, Kim YR, Yoo NJ and Lee SH:
Mutational analysis of DNMT3A gene in acute leukemias and common
solid cancers. APMIS. 121:85–94. 2013. View Article : Google Scholar
|
|
71
|
Kanai Y, Ushijima S, Kondo Y, Nakanishi Y
and Hirohashi S: DNA methyltransferase expression and DNA
methylation of CPG islands and peri-centromeric satellite regions
in human colorectal and stomach cancers. Int J Cancer. 91:205–212.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Hu J, Fan H, Liu D, Zhang S, Zhang F and
Xu H: DNMT3B promoter polymorphism and risk of gastric cancer. Dig
Dis Sci. 55:1011–1016. 2010. View Article : Google Scholar
|
|
73
|
Li H, Li W, Liu S, Zong S, Wang W, Ren J,
Li Q, Hou F and Shi Q: DNMT1, DNMT3A and DNMT3B polymorphisms
associated with gastric cancer risk: A systematic review and
meta-analysis. EBioMedicine. 13:125–131. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Tang H, Deng M, Tang Y and Xie X, Guo J,
Kong Y, Ye F, Su Q and Xie X: miR-200b and miR-200c as prognostic
factors and mediators of gastric cancer cell progression. Clin
Cancer Res. 19:5602–5612. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Zhang BG, Hu L, Zang MD, Wang HX, Zhao W,
Li JF, Su LP, Shao Z, Zhao X, Zhu ZG, et al: Helicobacter pylori
CagA induces tumor suppressor gene hypermethylation by upregulating
DNMT1 via AKT-NF-κB pathway in gastric cancer development.
Oncotarget. 7:9788–9800. 2016.PubMed/NCBI
|
|
76
|
Wallasch C, Crabtree JE, Bevec D, Robinson
PA, Wagner H and Ullrich A: Helicobacter pylori-stimulated EGF
receptor transactivation requires metalloprotease cleavage of
HB-EGF. Biochem Biophys Res Commun. 295:695–701. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Hino R, Uozaki H, Murakami N, Ushiku T,
Shinozaki A, Ishikawa S, Morikawa T, Nakaya T, Sakatani T, Takada
K, et al: Activation of DNA methyltransferase 1 by EBV latent
membrane protein 2A leads to promoter hypermethylation of PTEN gene
in gastric carcinoma. Cancer Res. 69:2766–2774. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Liang Q, Yao X, Tang S, Zhang J, Yau TO,
Li X, Tang CM, Kang W, Lung RW, Li JW, et al: Integrative
identification of Epstein-Barr virus-associated mutations and
epigenetic alterations in gastric cancer. Gastroenterology.
147:1350–62.e4. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Liu J, Zhu X, Xu X and Dai D: DNA promoter
and histone H3 methylation downregulate NGX6 in gastric cancer
cells. Med Oncol. 31:8172014. View Article : Google Scholar
|
|
80
|
Park YS, Jin MY, Kim YJ, Yook JH, Kim BS
and Jang SJ: The global histone modification pattern correlates
with cancer recurrence and overall survival in gastric
adenocarcinoma. Ann Surg Oncol. 15:1968–1976. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Lee H, Yoon SO, Jeong WY, Kim HK, Kim A
and Kim BH: Immunohistochemical analysis of polycomb group protein
expression in advanced gastric cancer. Hum Pathol. 43:1704–1710.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
He LJ, Cai MY, Xu GL, Li JJ, Weng ZJ, Xu
DZ, Luo GY, Zhu SL and Xie D: Prognostic significance of
overexpression of EZH2 and H3k27me3 proteins in gastric cancer.
Asian Pac J Cancer Prev. 13:3173–3178. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Kwon OH, Park JL, Kim M, Kim JH, Lee HC,
Kim HJ, Noh SM, Song KS, Yoo HS, Paik SG, et al: Aberrant
up-regulation of LAMB3 and LAMC2 by promoter demethylation in
gastric cancer. Biochem Biophys Res Commun. 406:539–545. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Komatsu S, Ichikawa D, Hirajima S, Nagata
H, Nishimura Y, Kawaguchi T, Miyamae M, Okajima W, Ohashi T,
Konishi H, et al: Overexpression of SMYD2 contributes to malignant
outcome in gastric cancer. Br J Cancer. 112:357–364. 2015.
View Article : Google Scholar :
|
|
85
|
Liu Y, Deng J, Luo X, Pan Y, Zhang L,
Zhang R and Liang H: Overexpression of SMYD3 was associated with
increased STAT3 activation in gastric cancer. Med Oncol.
32:4042015. View Article : Google Scholar
|
|
86
|
Liu H, Liu Y, Kong F, Xin W, Li X, Liang H
and Jia Y: Elevated levels of SET and MYND domain-containing
protein 3 are correlated with overexpression of transforming growth
factor-β1 in gastric cancer. J Am Coll Surg. 221:579–590. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Liu Y, Liu H, Luo X, Deng J, Pan Y and
Liang H: Overexpression of SMYD3 and matrix metalloproteinase-9 are
associated with poor prognosis of patients with gastric cancer.
Tumour Biol. 36:4377–4386. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Liu Y, Luo X, Deng J, Pan Y, Zhang L and
Liang H: SMYD3 overexpression was a risk factor in the biological
behavior and prognosis of gastric carcinoma. Tumour Biol.
36:2685–2694. 2015. View Article : Google Scholar
|
|
89
|
Cai L, Ma X, Huang Y, Zou Y and Chen X:
Aberrant histone methylation and the effect of Suv39H1 siRNA on
gastric carcinoma. Oncol Rep. 31:2593–2600. 2014.PubMed/NCBI
|
|
90
|
Fujii S, Ito K, Ito Y and Ochiai A:
Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by
increasing histone H3 methylation. J Biol Chem. 283:17324–17332.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Qi Y, Zhang X, Kang Y, Wu J, Chen J, Li H,
Guo Y, Liu B, Shao Z and Zhao X: Genome-wide transcriptional
profiling analysis reveals annexin A6 as a novel EZH2 target gene
involving gastric cellular proliferation. Mol Biosyst.
11:1980–1986. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Fujii S and Ochiai A: Enhancer of zeste
homolog 2 downregulates E-cadherin by mediating histone H3
methylation in gastric cancer cells. Cancer Sci. 99:738–746. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Tong Y, Li Y, Gu H, Wang C, Liu F, Shao Y,
Li J, Cao L and Li F: Microchidia protein 2, MORC2, downregulates
the cytoskeleton adapter protein, ArgBP2, via histone methylation
in gastric cancer cells. Biochem Biophys Res Commun. 467:821–827.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Bai J, Chen J, Ma M, Cai M, Xu F, Wang G,
Tao K and Shuai X: Inhibiting enhancer of zeste homolog 2 promotes
cellular senescence in gastric cancer cells SGC-7901 by activation
of p21 and p16. DNA Cell Biol. 33:337–344. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Jie B, Weilong C, Ming C, Fei X, Xinghua
L, Junhua C, Guobin W, Kaixiong T and Xiaoming S: Enhancer of zeste
homolog 2 depletion induces cellular senescence via histone
demethylation along the INK4/ARF locus. Int J Biochem Cell Biol.
65:104–112. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Lu H, Sun J, Wang F, Feng L, Ma Y, Shen Q,
Jiang Z, Sun X, Wang X and Jin H: Enhancer of zeste homolog 2
activates wnt signaling through downregulating CXXC finger protein
4. Cell Death Dis. 4:e7762013. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Lu H, Jin W, Sun J, Feng L, Lan H, Shen Q,
Ma Y, Li J, Yue Y, Jin H, et al: New tumor suppressor CXXC finger
protein 4 inactivates mitogen activated protein kinase signaling.
FEBS Lett. 588:3322–3326. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Akiyama Y, Koda Y, Byeon SJ, Shimada S,
Nishikawaji T, Sakamoto A, Chen Y, Kojima K, Kawano T, Eishi Y, et
al: Reduced expression of SET7/9, a histone mono-methyltransferase,
is associated with gastric cancer progression. Oncotarget.
7:3966–3983. 2016.
|
|
99
|
Zeng J, Ge Z, Wang L, Li Q, Wang N,
Björkholm M, Jia J and Xu D: The histone demethylase RBP2 is
overexpressed in gastric cancer and its inhibition triggers
senescence of cancer cells. Gastroenterology. 138:981–992. 2010.
View Article : Google Scholar
|
|
100
|
Wang Z, Tang F, Qi G, Yuan S, Zhang G,
Tang B and He S: KDM5B is overexpressed in gastric cancer and is
required for gastric cancer cell proliferation and metastasis. Am J
Cancer Res. 5:87–100. 2014.
|
|
101
|
Li Y, Tian X, Sui CG, Jiang YH, Liu YP and
Meng FD: Interference of lysine-specific demethylase 1 inhibits
cellular invasion and proliferation in vivo in gastric cancer
MKN-28 cells. Biomed Pharmacother. 82:498–508. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Yang H, Liu Z, Yuan C, Zhao Y, Wang L, Hu
J, Xie D, Wang L and Chen D: Elevated JMJD1A is a novel predictor
for prognosis and a potential therapeutic target for gastric
cancer. Int J Clin Exp Pathol. 8:11092–11099. 2015.PubMed/NCBI
|
|
103
|
Hu CE, Liu YC, Zhang HD and Huang GJ:
JMJD2A predicts prognosis and regulates cell growth in human
gastric cancer. Biochem Biophys Res Commun. 449:1–7. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Li W, Zhao L, Zang W, Liu Z, Chen L, Liu
T, Xu D and Jia J: Histone demethylase JMJD2B is required for tumor
cell proliferation and survival and is overexpressed in gastric
cancer. Biochem Biophys Res Commun. 416:372–378. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Zhao L, Li W, Zang W, Liu Z, Xu X, Yu H,
Yang Q and Jia J: JMJD2B promotes epithelial-mesenchymal transition
by cooperating with β-catenin and enhances gastric cancer
metastasis. Clin Cancer Res. 19:6419–6429. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Taverna SD, Li H, Ruthenburg AJ, Allis CD
and Patel DJ: How chromatin-binding modules interpret histone
modifications: Lessons from professional pocket pickers. Nat Struct
Mol Biol. 14:1025–1040. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
He C, Xu J, Zhang J, Xie D, Ye H, Xiao Z,
Cai M, Xu K, Zeng Y, Li H, et al: High expression of trimethylated
histone H3 lysine 4 is associated with poor prognosis in
hepatocellular carcinoma. Hum Pathol. 43:1425–1435. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Zee BM, Levin RS, Xu B, LeRoy G, Wingreen
NS and Garcia BA: In vivo residue-specific histone methylation
dynamics. J Biol Chem. 285:3341–3350. 2010. View Article : Google Scholar :
|
|
109
|
Tsukada Y, Fang J, Erdjument-Bromage H,
Warren ME, Borchers CH, Tempst P and Zhang Y: Histone demethylation
by a family of JmjC domain-containing proteins. Nature.
439:811–816. 2006. View Article : Google Scholar
|
|
110
|
Huang J and Berger SL: The emerging field
of dynamic lysine methylation of non-histone proteins. Curr Opin
Genet Dev. 18:152–158. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Tan JZ, Yan Y, Wang XX, Jiang Y and Xu HE:
EZH2: Biology, disease, and structure-based drug discovery. Acta
Pharmacol Sin. 35:161–174. 2014. View Article : Google Scholar :
|
|
112
|
Ning X, Shi Z, Liu X, Zhang A, Han L,
Jiang K, Kang C and Zhang Q: DNMT1 and EZH2 mediated methylation
silences the microRNA-200b/a/429 gene and promotes tumor
progression. Cancer Lett. 359:198–205. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Viré E, Brenner C, Deplus R, Blanchon L,
Fraga M, Didelot C, Morey L, Van Eynde A, Bernard D, Vanderwinden
JM, et al: The Polycomb group protein EZH2 directly controls DNA
methylation. Nature. 439:871–874. 2006. View Article : Google Scholar
|
|
114
|
Ma J, Wang JD, Zhang WJ, Zou B, Chen WJ,
Lam CS, Chen MH, Pang R, Tan VP, Hung IF, et al: Promoter
hypermethylation and histone hypoacetylation contribute to
pancreatic-duodenal homeobox 1 silencing in gastric cancer.
Carcinogenesis. 31:1552–1560. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Meng CF, Zhu XJ, Peng G and Dai DQ:
Promoter histone H3 lysine 9 di-methylation is associated with DNA
methylation and aberrant expression of p16 in gastric cancer cells.
Oncol Rep. 22:1221–1227. 2009.PubMed/NCBI
|
|
116
|
Watanabe Y, Toyota M, Kondo Y, Suzuki H,
Imai T, Ohe-Toyota M, Maruyama R, Nojima M, Sasaki Y, Sekido Y, et
al: PRDM5 identified as a target of epigenetic silencing in
colorectal and gastric cancer. Clin Cancer Res. 13:4786–4794. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Cho HS, Shimazu T, Toyokawa G, Daigo Y,
Maehara Y, Hayami S, Ito A, Masuda K, Ikawa N, Field HI, et al:
Enhanced HSP70 lysine methylation promotes proliferation of cancer
cells through activation of Aurora kinase B. Nat Commun.
3:10722012. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Hamamoto R, Toyokawa G, Nakakido M, Ueda K
and Nakamura Y: SMYD2-dependent HSP90 methylation promotes cancer
cell proliferation by regulating the chaperone complex formation.
Cancer Lett. 351:126–133. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Huang J, Perez-Burgos L, Placek BJ,
Sengupta R, Richter M, Dorsey JA, Kubicek S, Opravil S, Jenuwein T
and Berger SL: Repression of p53 activity by Smyd2-mediated
methylation. Nature. 444:629–632. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Saddic LA, West LE, Aslanian A, Yates JR
III, Rubin SM, Gozani O and Sage J: Methylation of the
retinoblastoma tumor suppressor by SMYD2. J Biol Chem.
285:37733–37740. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Cho HS, Hayami S, Toyokawa G, Maejima K,
Yamane Y, Suzuki T, Dohmae N, Kogure M, Kang D, Neal DE, et al: RB1
methylation by SMYD2 enhances cell cycle progression through an
increase of RB1 phosphorylation. Neoplasia. 14:476–486. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Piao L, Kang D, Suzuki T, Masuda A, Dohmae
N, Nakamura Y and Hamamoto R: The histone methyltransferase SMYD2
methylates PARP1 and promotes poly(ADP-ribosyl)ation activity in
cancer cells. Neoplasia. 16:257–264.e2. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Mazur PK, Reynoird N, Khatri P, Jansen PW,
Wilkinson AW, Liu S, Barbash O, Van Aller GS, Huddleston M, Dhanak
D, et al: SMYD3 links lysine methylation of MAP3K2 to Ras-driven
cancer. Nature. 510:283–287. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Easwaran H, Tsai HC and Baylin SB: Cancer
epigenetics: Tumor heterogeneity, plasticity of stem-like states,
and drug resistance. Mol Cell. 54:716–727. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Compare D, Rocco A, Liguori E, D'Armiento
FP, Persico G, Masone S, Coppola-Bottazzi E, Suriani R, Romano M
and Nardone G: Global DNA hypomethylation is an early event in
Helicobacter pylori-related gastric carcinogenesis. J Clin Pathol.
64:677–682. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Yamashita S, Tsujino Y, Moriguchi K,
Tatematsu M and Ushijima T: Chemical genomic screening for
methylation-silenced genes in gastric cancer cell lines using
5-aza-2′-deoxycytidine treatment and oligonucleotide microarray.
Cancer Sci. 97:64–71. 2006. View Article : Google Scholar
|
|
127
|
Sepulveda AR, Yao Y, Yan W, Park DI, Kim
JJ, Gooding W, Abudayyeh S and Graham DY: CpG methylation and
reduced expression of O6-methylguanine DNA
methyltransferase is associated with Helicobacter pylori infection.
Gastroenterology. 138:1836–1844. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Hur K, Niwa T, Toyoda T, Tsukamoto T,
Tatematsu M, Yang HK and Ushijima T: Insufficient role of cell
proliferation in aberrant DNA methylation induction and involvement
of specific types of inflammation. Carcinogenesis. 32:35–41. 2011.
View Article : Google Scholar
|
|
129
|
Nardone G, Rocco A and Malfertheiner P:
Review article: Helicobacter pylori and molecular events in
precancerous gastric lesions. Aliment Pharmacol Ther. 20:261–270.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Angrisano T, Lembo F, Peluso S, Keller S,
Chiariotti L and Pero R: Helicobacter pylori regulates iNOS
promoter by histone modifications in human gastric epithelial
cells. Med Microbiol Immunol (Berl). 201:249–257. 2012. View Article : Google Scholar
|
|
131
|
Han F, Ren J, Zhang J, Sun Y, Ma F, Liu Z,
Yu H, Jia J and Li W: JMJD2B is required for Helicobacter
pylori-induced gastric carcinogenesis via regulating COX-2
expression. Oncotarget. 7:38626–38637. 2016.PubMed/NCBI
|
|
132
|
Bass AJ, Thorsson V, Shmulevich I,
Reynolds SM, Miller M, Bernard B, Hinoue T, Laird PW, Curtis C,
Shen H, et al Cancer Genome Atlas Research Network: Comprehensive
molecular characterization of gastric adenocarcinoma. Nature.
513:202–209. 2014. View Article : Google Scholar :
|
|
133
|
Kaneda A, Matsusaka K, Aburatani H and
Fukayama M: Epstein-Barr virus infection as an epigenetic driver of
tumorigenesis. Cancer Res. 72:3445–3450. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Sudo M, Chong JM, Sakuma K, Ushiku T,
Uozaki H, Nagai H, Funata N, Matsumoto Y and Fukayama M: Promoter
hyper-methylation of E-cadherin and its abnormal expression in
Epstein-Barr virus-associated gastric carcinoma. Int J Cancer.
109:194–199. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Osawa T, Chong JM, Sudo M, Sakuma K,
Uozaki H, Shibahara J, Nagai H, Funata N and Fukayama M: Reduced
expression and promoter methylation of p16 gene in Epstein-Barr
virus-associated gastric carcinoma. Jpn J Cancer Res. 93:1195–1200.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Ryan JL, Jones RJ, Kenney SC, Rivenbark
AG, Tang W, Knight ER, Coleman WB and Gulley ML: Epstein-Barr
virus-specific methylation of human genes in gastric cancer cells.
Infect Agent Cancer. 5:272010. View Article : Google Scholar
|
|
137
|
Matsusaka K, Kaneda A, Nagae G, Ushiku T,
Kikuchi Y, Hino R, Uozaki H, Seto Y, Takada K, Aburatani H, et al:
Classification of Epstein-Barr virus-positive gastric cancers by
definition of DNA methylation epigenotypes. Cancer Res.
71:7187–7197. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Ballestar E and Esteller M: SnapShot: The
human DNA methylome in health and disease. Cell. 135:1144–1144.e1.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Schneider BJ, Shah MA, Klute K, Ocean A,
Popa E, Altorki NK, Lieberman MD, Schreiner A, Yantiss RK, Christos
PJ, et al: Phase I study of epigenetic priming with azacitidine
prior to standard neoadjuvant chemotherapy for patients with
resectable gastric and esophageal adenocarcinoma. Clin Cancer Res.
View Article : Google Scholar : Epub ahead of
print.
|
|
140
|
Liu J, Xie YS, Wang FL, Zhang LJ, Zhang Y
and Luo HS: Cytotoxicity of 5-Aza-2′-deoxycytidine against gastric
cancer involves DNA damage in an ATM-P53 dependent signaling
pathway and demethylation of P16INK4A. Biomed
Pharmacother. 67:78–87. 2013. View Article : Google Scholar
|
|
141
|
Shin DY, Kim GY, Kim CG, Kim WJ, Kang HS
and Choi YH: Anti-invasive effects of decitabine, a DNA
methyltransferase inhibitor, through tightening of tight junctions
and inhibition of matrix metalloproteinase activities in AGS human
gastric carcinoma cells. Oncol Rep. 28:1043–1050. 2012.PubMed/NCBI
|
|
142
|
Tan W, Zhou W, Yu HG, Luo HS and Shen L:
The DNA methyltransferase inhibitor zebularine induces
mitochondria-mediated apoptosis in gastric cancer cells in vitro
and in vivo. Biochem Biophys Res Commun. 430:250–255. 2013.
View Article : Google Scholar
|
|
143
|
Takeshima H, Wakabayashi M, Hattori N,
Yamashita S and Ushijima T: Identification of coexistence of DNA
methylation and H3K27me3 specifically in cancer cells as a
promising target for epigenetic therapy. Carcinogenesis.
36:192–201. 2015. View Article : Google Scholar
|
|
144
|
Cheng LL, Itahana Y, Lei ZD, Chia NY, Wu
Y, Yu Y, Zhang SL, Thike AA, Pandey A, Rozen S, et al: TP53 genomic
status regulates sensitivity of gastric cancer cells to the histone
methylation inhibitor 3-deazaneplanocin A (DZNep). Clin Cancer Res.
18:4201–4212. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Kaminskas E, Farrell AT, Wang YC, Sridhara
R and Pazdur R: FDA drug approval summary: Azacitidine
(5-azacytidine, Vidaza) for injectable suspension. Oncologist.
10:176–182. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Steensma DP, Baer MR, Slack JL, Buckstein
R, Godley LA, Garcia-Manero G, Albitar M, Larsen JS, Arora S,
Cullen MT, et al: Multicenter study of decitabine administered
daily for 5 days every 4 weeks to adults with myelodysplastic
syndromes: The alternative dosing for outpatient treatment (ADOPT)
trial. J Clin Oncol. 27:3842–3848. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Erdmann A, Halby L, Fahy J and Arimondo
PB: Targeting DNA methylation with small molecules: What's next? J
Med Chem. 58:2569–2583. 2015. View Article : Google Scholar
|
|
148
|
Navada SC, Steinmann J, Lübbert M and
Silverman LR: Clinical development of demethylating agents in
hematology. J Clin Invest. 124:40–46. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Chen XL, Wang FM, Li JJ, He XY, Liu XY and
Ma LB: The effect of two nucleoside antitumor drugs on the
proliferation and DNA methylation of human gastric cancer cells.
Oncol Lett. 10:1919–1923. 2015.PubMed/NCBI
|
|
150
|
Karahoca M and Momparler RL:
Pharmacokinetic and pharmacodynamic analysis of
5-aza-2′-deoxycytidine (decitabine) in the design of its
dose-schedule for cancer therapy. Clin Epigenetics. 5:32013.
View Article : Google Scholar
|
|
151
|
Si J, Boumber YA, Shu J, Qin T, Ahmed S,
He R, Jelinek J and Issa JP: Chromatin remodeling is required for
gene reactivation after decitabine-mediated DNA hypomethylation.
Cancer Res. 70:6968–6977. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Plumb JA, Strathdee G, Sludden J, Kaye SB
and Brown R: Reversal of drug resistance in human tumor xenografts
by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene
promoter. Cancer Res. 60:6039–6044. 2000.PubMed/NCBI
|
|
153
|
Wu FL, Li RT, Yang M, Yue GF, Wang HY, Liu
Q, Cui FB, Wu PY, Ding H, Yu LX, et al: Gelatinases-stimuli
nanoparticles encapsulating 5-fluorouridine and
5-aza-2′-deoxycytidine enhance the sensitivity of gastric cancer
cells to chemical therapeutics. Cancer Lett. 363:7–16. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Chen M, Shabashvili D, Nawab A, Yang SX,
Dyer LM, Brown KD, Hollingshead M, Hunter KW, Kaye FJ, Hochwald SN,
et al: DNA methyltransferase inhibitor, zebularine, delays tumor
growth and induces apoptosis in a genetically engineered mouse
model of breast cancer. Mol Cancer Ther. 11:370–382. 2012.
View Article : Google Scholar
|
|
155
|
Ben-Kasus T, Ben-Zvi Z, Marquez VE, Kelley
JA and Agbaria R: Metabolic activation of zebularine, a novel DNA
methylation inhibitor, in human bladder carcinoma cells. Biochem
Pharmacol. 70:121–133. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Plass C, Pfister SM, Lindroth AM,
Bogatyrova O, Claus R and Lichter P: Mutations in regulators of the
epigenome and their connections to global chromatin patterns in
cancer. Nat Rev Genet. 14:765–780. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Greiner D, Bonaldi T, Eskeland R, Roemer E
and Imhof A: Identification of a specific inhibitor of the histone
methyltransferase SU(VAR)3–9. Nat Chem Biol. 1:143–145. 2005.
View Article : Google Scholar
|
|
158
|
Glazer RI, Hartman KD, Knode MC, Richard
MM, Chiang PK, Tseng CK and Marquez VE: 3-Deazaneplanocin: A new
and potent inhibitor of S-adenosylhomocysteine hydrolase and its
effects on human promyelocytic leukemia cell line HL-60. Biochem
Biophys Res Commun. 135:688–694. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Tan J, Yang X, Zhuang L, Jiang X, Chen W,
Lee PL, Karuturi RK, Tan PB, Liu ET and Yu Q: Pharmacologic
disruption of Polycomb-repressive complex 2-mediated gene
repression selectively induces apoptosis in cancer cells. Genes
Dev. 21:1050–1063. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Sun F, Lee L, Zhang Z, Wang X, Yu Q, Duan
X and Chan E: Preclinical pharmacokinetic studies of
3-deazaneplanocin A, a potent epigenetic anticancer agent, and its
human pharmacokinetic prediction using GastroPlus™. Eur J Pharm
Sci. 77:290–302. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
McCabe MT, Ott HM, Ganji G, Korenchuk S,
Thompson C, Van Aller GS, Liu Y, Graves AP, Della Pietra A III,
Diaz E, et al: EZH2 inhibition as a therapeutic strategy for
lymphoma with EZH2-activating mutations. Nature. 492:108–112. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Chen YT, Zhu F, Lin WR, Ying RB, Yang YP
and Zeng LH: The novel EZH2 inhibitor, GSK126, suppresses cell
migration and angiogenesis via down-regulating VEGF-A. Cancer
Chemother Pharmacol. 77:757–765. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Knutson SK, Warholic NM, Wigle TJ, Klaus
CR, Allain CJ, Raimondi A, Porter Scott M, Chesworth R, Moyer MP,
Copeland RA, et al: Durable tumor regression in genetically altered
malignant rhabdoid tumors by inhibition of methyltransferase EZH2.
Proc Natl Acad Sci USA. 110:7922–7927. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Qi W, Chan H, Teng L, Li L, Chuai S, Zhang
R, Zeng J, Li M, Fan H, Lin Y, et al: Selective inhibition of Ezh2
by a small molecule inhibitor blocks tumor cells proliferation.
Proc Natl Acad Sci USA. 109:21360–21365. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Bai J, Ma M, Cai M, Xu F, Chen J, Wang G,
Shuai X and Tao K: Inhibition enhancer of zeste homologue 2
promotes senescence and apoptosis induced by doxorubicin in p53
mutant gastric cancer cells. Cell Prolif. 47:211–218. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Lee MG, Wynder C, Schmidt DM, McCafferty
DG and Shiekhattar R: Histone H3 lysine 4 demethylation is a target
of nonselective antidepressive medications. Chem Biol. 13:563–567.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Schmidt DM and McCafferty DG:
trans-2-Phenylcyclopropylamine is a mechanism-based inactivator of
the histone demethylase LSD1. Biochemistry. 46:4408–4416. 2007.
View Article : Google Scholar : PubMed/NCBI
|
